Oncolytics Biotech Inc T.ONC

RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

[Noteable]

October 2024 -  WuXi Biologics Faces Uncertain Future in the U.S. After Bi-partisan Support Passses BIOSECURE ACT 

" ..unless WuXi Biologics needs the capital, selling its U.S. facilities would not help the company in the short term."

https://www.fiercepharma.com/pharma/gilead-withdraws-trodelvy-bladder-cancer-after-trial-flop

" Total foreign direct investment in China had already been on the decline since June 2023, and intensified geopolitical tensions between China and the U.S. arising from the BIOSECURE Act might worsen the current situation in China, according to Chia Lin, an APAC analyst from GlobalData’s Health Economics & Market Access Team. “After the Act was announced, several companies such as Eli Lilly and Vertex have discussed strategies to diversify production away from Chinese manufacturers named under the Act,” Lin wrote in an email to BioSpace. “Chinese manufacturer WuXi has also discussed moving its business units outside of the U.S.” In 2023, WuXi Apptec generated around $26.13 billion from U.S. contracts, accounting for 65% of its total revenue.

“This (move away from China) could unlock a new wave of investment in CRO and CDMO in the West to try to fill that gap,” according to  Cody Powers, principal and portfolio and business development practice lead at ZS Associates. 

Looking further ahead, there is a possibility that follow-on legislation could impose more restrictions and bring about a “seismic shift,” he said, in which East and West each cultivate their own biopharma ecosystems for research and development, operating under their own regulatory frameworks and dictating the extent of innovation exchange.

https://www.biospace.com/policy/biosecure-act-could-signal-a-seismic-shift-for-biopharma-in-us-and-china